Stop TB Partnership launches online consultation to update the Global Plan to End TB 2016-2020; Deadline for submission: 19 July 2019

TB LAM can help close the deadly TB testing gap.

Activists storm the corporate stall of Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) at the 9^th South African AIDS Conference.

Advocates request full access to the terms of the agreement granting Mylan the rights to commercialize pretomanid.

Investigational drug pretomanid is under regulatory review by FDA for treatment of XDR-TB and treatment-intolerant or non-responsive MDR-TB as part of a new investigational regimen.

Advocates request an urgent in-person meeting with the WHO leadership to discuss concrete actions to address technical and guideline development process-related issues previously raised.

WHO launches a multisectoral accountability framework to end TB as requested by the World Health Assembly and the UN General Assembly in 2018.

The launch of the Declaration is a significant step in recognizing the urgent need to adopt a human rights-based approach to TB and fund human rights-based interventions that overcome barriers to universal access.

Community capacity building modules to accelerate the response to drug-resistant TB launched at WHO meeting of national TB program managers and partners in the South-East Asia region.

TB CAB releases document outlining key considerations regarding pretomanid in anticipation of FDA public advisory committee meeting on the TB Alliance's new drug application for pretomanid.